Novartis Ag

Cytomx Therapeutics, Inc.

Genentech, Inc.

Sloan-kettering Institute for Cancer Research

Dylan L Daniel

Madan M Paidhungat

Sayantan Mitra

Hsin Wang

Nicole G Lapuyade

Erwan Le Scolan

Hikmat Haizar Assi

Walter A Bogdanoff

Na Cai

Thomas Huber

Bernhard Hubert Geierstanger

Tinya Abrams

Weijia Ou

Steven Bruce Cohen

William Mallet

Kathrin Ulrike Tissot-Daguette

Siew Ho Schleyer

Matthew John Meyer

Catrin Finner

Avi J Ashkenazi

James Clifford Sutton

Theresa Shek

Johanna Joyce

Alexey Yevgenyevich Berezhnoy

Provided herein are activatable cytokine constructs that include: (a) a first monomer construct comprising a first mature cytokine protein (CP1), a first cleavable moiety (CM1), and a first dimerization domain (DD1), wherein the CM1 is positioned between the CP1 and the DD1; and (b) a second monomer construct comprising a second mature cytokine protein (CP2), a second cleavable moiety (CM2), and a second dimerization domain (DD2), where the CM2 is positioned between the CP2 and the DD2, where: the CM1 and the CM2 function as a substrate for a protease; the DD1 and the DD2 bind each other; and where the ACC is characterized by a reduction in at least one activity of the CP1 and/or CP2 as compared to a control level of the at least one activity of the CP1 and/or CP2.

Activatable cytokine constructs and related compositions and methods

The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.

CKIT antibody drug conjugates

Provided herein are activatable cytokine constructs that include: (a) a first monomer construct comprising a first peptide mask (PM1), a third cleavable moiety (CM3), a first mature cytokine protein (CP1), a first cleavable moiety (CM1), and a first dimerization domain (DD1), wherein the CM1 is positioned between the CP1 and the DD1, and the CM3 is positioned between the PM1 and CP1; and (b) a second monomer construct comprising a second mature cytokine protein (CP2), a second cleavable moiety (CM2), and a second dimerization domain (DD2), where the CM2 is positioned between the CP2 and the DD2, where: the DD1 and the DD2 bind each other; and where the ACC is characterized by a reduction in at least one activity of the CP1 and/or CP2 as compared to a control level of the at least one activity of the CP1 and/or CP2.

Masked activatable interferon constructs

The present invention provides a compound of formula I; 

CSF-1R inhibitors for treatment of brain tumors

The present invention is directed to compositions of matter useful for the treatment of non-Hodgkin's lymphoma in mammals and to methods of using those compositions for the same.

Compositions and methods for treatment of non-Hodgkin's lymphoma

Growing community of inventors

San Francisco, CA, United States of America

Dylan L Daniel